Every trading day, be ready to attack the market instead of reacting to the
market.

You will know where the key technical resistance and support levels are and what
the market is likely to do next. iStock will arm you with a target list of stocks
to buy and sell - right now - based on our exclusive, proprietary trading models.
You will also receive monthly ETF model portfolio and trend trader model portfolio

The Metrics of Growth in China Biopharma

The healthcare market in China is certainly growing, and so are the
companies that serve the market, though the parameters used to measure
that growth may differ for each biopharma. For public companies, the
quarterly earning statement delivers a significant analysis of a
biopharma's measure of success, and last week, China biopharmas
continued to roll out Q1 reports that were remarkable for their
uniformly positive news. But for private companies, the metrics have to
be different. In ChinaBio® Today last week, we published examples of
both types of stories.

GenePharma, a young and growing private company that provides research
tools to the hot siRNA market, was the subject of a profile that
included an exclusive interview with its founder and CEO, Dr. Peter
Zhang (see story).
GenePharma has recently made two announcements that testify to its
ambitious plans: the company is opening a new manufacturing a facility
in BioBay Park near Suzhou, and it acquired a patent license from
Alnylam (NSDQ: alny).
The patent license allows GenePharma to sell its siRNA products
worldwide. Combining low prices with excellent service – and an
explosive market for siRNA products – GenePharma is well-positioned for
growth. The company is also a textbook example of the sea turtle
phenomenon, the convergence of recent historical and economic trends
that has made China a preferred location for siting biopharma
enterprises.

No fewer than four China-based, American-listed biopharmas disclosed
their Q1 financial reports during the last week. Each announced revenue
growth of at least 39%, and two were able to say their sales had more
than doubled.

China Sky One (OTCBB:cski.ob),
with a remarkable 140% jump in revenue ($12.4 million) and a 170% climb
in net income ($3.9 million), wins the Most Improved award for
companies reporting this week (see story).
To continue its growth, China Sky One completed two acquisitions in the
beginning of Q2 that will continue its growth. One acquisition,
Heilongjiang Tianlong Pharma, is a competitor of China Sky One in the
niche of externally-applied (patches, sprays, ointments) drugs, and the
other addition, Heilongjiang Haina Pharma, has a Good Supply Practice
license that allows distribution of drugs. Meanwhile, China Sky One
continues to expand its in-vitro diagnostic test offerings, and the
company is applying for listing on the American Stock Exchange.
Presently, China Sky One is listed on the OTC Bulletin Board.

Fundamental data is provided by Zacks
Investment Research, and Commentary, news and Press Releases provided by
YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not
intended for trading purposes or advice. iStockAnalyst.com is not an investment
adviser and does not provide, endorse or review any information or data contained
herein.
The blog articles are opinions by respective blogger. By using this site you are
agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither
iStockAnalyst nor any of its independent providers is liable for any informational
errors, incompleteness, or delays, or for any actions taken in reliance on information
contained herein. You are solely responsible for the investment decisions made by
you and the consequences resulting therefrom. By accessing the iStockAnalyst.com
site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based
on EOD data.